Calcitonin Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Calcitonin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | 8,481,546 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | 7,220,862 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | 8,754,096 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | 9,499,545 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
